一、被提名人具备上市公司运作的基本知识，熟悉相关法律、 行政法规、规章及其他规范性文件，具有 5 年以上法律、经济、 会计、财务、管理或者其他履行独立董事职责所必需的工作经验。 被提名人已经参加培训并取得证券交易所认可的相关培训 证明材料。 二、被提名人任职资格符合下列法律、行政法规和部门规章 的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的 规定（如适用）； （三）中国证监会《上市公司独立董事管理办法》、上海证 券交易所自律监管规则以及公司章程有关独立董事任职资格和 条件的相关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部 独立董事提名人声明与承诺 提名人中国医药健康产业股份有限公司董事会，现提名王瑞 华先生、闫永红女士、李志勇先生为中国医药健康产业股份有限 公司第十届董事会独立董事候选人，并已充分了解被提名人职业、 学历、职称、详细的工作经历、全部兼职、有无重大失信等不良 记录等情况。被提名人已同意出任国医药健康产业股份有限公司 第十届董事会独立董事候选人（参见上述独立董事候选人声明）。 提名人认为，被提名人具备独立董事任 ...

证券代码：600056 证券简称：中国医药 公告编号：临 2026-009 号 中国医药健康产业股份有限公司 关于召开2026年第一次临时股东会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东会类型和届次 2026年第一次临时股东会 (二) 股东会召集人：董事会 (三) 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结 合的方式 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 2 月 9 日 至2026 年 2 月 9 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东会召开当日的 9:15-15:00。 (六) 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 1 股东会召开日期：2026年2月9日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、会议召开情况 (一)中国医药健康产业股份有限公司(以下简称"公司")第九届董事会第35 次会议（以下简称"本次会议"）于2026年1月23日以现场结合通讯方式召开，会 议由董事长、总经理杨光先生主持，公司相关高级管理人员列席了本次会议。 证券代码：600056 证券简称：中国医药 公告编号：临2026-008号 中国医药健康产业股份有限公司 第九届董事会第 35 次会议决议公告 (二)本次会议通知于2026年1月17日以邮件、短信、电话或传真的方式向全 体董事发出。 (三)本次会议应参加会议董事8名，实际参加会议董事8名。 (四)本次会议的召开符合《公司法》及《公司章程》的有关规定，会议决议 为有效决议。 二、会议审议情况 本次会议审议并通过如下议案： （一）审议通过了《关于董事会换届选举第十届董事会非独立董事候选人的 议案》。 经决议，董事会同意将提名杨光先生、潘臻先生、孙卓女士、杨新先生为公 司第十届董事会非独立董事候选人的事项提交公司 2026 年第一次临时股东会审 ...

Core Viewpoint - The report highlights the significant growth and development of China's Contract Research Organization (CRO) industry, driven by a comprehensive policy framework and regulatory reforms that enhance innovation and operational efficiency in the pharmaceutical sector [1][3][9]. Group 1: Industry Overview - The main listed companies in China's CRO industry include WuXi AppTec (603259.SH), Kanglong Chemical (300759.SZ), Tigermed (300347.SZ), Kelaiying (002821.SZ), Zhaoyan New Drug (603127.SH), Jiuzhou Pharmaceutical (603456.SH), Haoyuan Pharmaceutical (688131.SH), Boteng Co., Ltd. (300363.SZ), Chengdu XianDao (688222.SH), and Yaoshi Technology (300725.SZ) [1]. - The CRO industry is recognized as a strategic emerging industry that supports pharmaceutical innovation, transitioning China from a major pharmaceutical market to a strong one [1]. Group 2: Policy Framework - The policy framework for the CRO industry is centered around the National Medical Products Administration (NMPA) and includes collaboration with other regulatory bodies such as the National Health Commission (NHC) and the Drug Administration (CDR) [3]. - Key regulatory measures include the Marketing Authorization Holder (MAH) system, implicit licensing for clinical trials, Good Laboratory Practice (GLP) and Good Clinical Practice (GCP) certifications, and priority review and approval processes [3]. Group 3: Industry Support Policies - National policies provide financial support through initiatives like the "Major New Drug Creation" program, tax reductions for high-tech enterprises, and increased deductions for R&D expenses, which lower operational costs for the industry [6]. - Local governments implement differentiated policies that align with regional industrial characteristics, including subsidies for innovative drug development and funding for CRO platform construction [6]. Group 4: Drug Review Reforms - Recent reforms in drug review processes have significantly improved approval efficiency, reducing the average clinical trial review time from 420 days to 30 days in pilot areas, and addressing a backlog of 22,000 cases [9][12]. - The definition of new drugs has shifted from "China New" to "Global New," aligning with international standards and enhancing the quality of innovation [12]. Group 5: Future Trends - The future of the CRO industry in China is expected to be driven by a robust policy framework, with trends including deeper collaboration in service models, increased application of AI and digital platforms, and a focus on specialized market segments [13]. - The competitive landscape is anticipated to evolve with the rise of domestic leaders and accelerated internationalization, benefiting from improved mechanisms for mutual recognition of clinical trial data [13].

Core Insights - The JPM conference highlighted breakthroughs in ADC, IO dual antibodies, and GLP-1 technologies by Chinese pharmaceutical companies, enabling them to expand globally through licensing and collaborative development [1] - Leading companies have successfully organized their international operations, with some biotech firms achieving breakthroughs in niche areas [1] - The CXO sector is experiencing significant growth, with companies leveraging the CRDMO model and global production capacity, resulting in a continuous increase in orders [1] - By 2026, overseas bases are expected to be densely operational, marking the beginning of a commercialization phase for the industry [1] - Overall, the Chinese pharmaceutical industry is at the starting point of a global value reassessment, with 2026 identified as a critical year for validating transformation outcomes [1]

Core Insights - The international competitiveness of domestic pharmaceutical companies in China is continuously improving, driven by new technologies and supportive national policies for innovative drug development [1][2] - The CXO sector is expected to see significant performance turning points as companies with high overseas business ratios are favored [1] Group 1: Industry Trends - The JPM conference highlighted breakthroughs in technologies such as ADC, IO dual antibodies, and GLP-1, enabling Chinese pharmaceutical companies to expand globally through licensing and collaborative development [1] - Major companies like BeiGene have successfully established international operations, while some biotech firms have achieved breakthroughs in niche areas [1] - The Chinese pharmaceutical industry is at the starting point of a global value reassessment, with 2026 being a critical year for validating transformation outcomes [1] Group 2: Domestic Pharmaceutical Companies - Domestic pharmaceutical companies are accelerating their globalization, characterized by several core trends: 1) Comprehensive iteration of technology platforms such as ADC, multi-antibodies, and small nucleic acids, leading to multiple BIC/FIC potential assets 2) Accelerated internationalization with over $10 billion in transactions with multinational corporations (MNCs) and a continuous rise in innovative drug licensing revenues 3) The year 2026 will see a concentrated period of catalysts for domestic companies, with many initiating global registration studies, key data readouts, and new product applications, showcasing both individual breakthroughs and overall sector acceleration [1] Group 3: CXO Sector Developments - The JPM conference underscored a historic opportunity for the Chinese CXO industry to transition from a "cost advantage" model to a "technology + scale" dual-driven approach [2] - Chinese CXO companies are evolving from "intermediate suppliers" to "global innovation enablers" through their one-stop service platform capabilities in areas like ADC, dual antibodies, and GLP-1 [2] - By 2026, both domestic and international innovations are expected to enter a concentrated catalyst period, with Chinese CXO companies experiencing sustained growth in orders and entering a phase of overseas capacity release [2]

Core Viewpoint - The announcement from China Pharmaceutical regarding the acquisition of 70% of Shanghai Zezheng Pharmaceutical Technology Co., Ltd. highlights significant challenges including a sharp decline in the target company's performance, high valuation, business transformation risks, and integration difficulties [1][4]. Financial Performance - The target company is expected to see a notable decline in performance, with projected revenues of approximately 257 million yuan and 107 million yuan for 2024 and 2025 respectively, and net profits of 39.34 million yuan and -40.85 million yuan [1]. - In 2025, the target company's revenue is anticipated to drop by 31.45 million yuan to 226 million yuan, a decrease of 12.24%, while net profit is expected to plummet by 29.89 million yuan to 9.44 million yuan, a staggering decline of 75.99% [1]. - The target company is projected to achieve a significant profit of 50.29 million yuan in Q4 2025, indicating a "V-shaped recovery" with a notable "year-end rush" characteristic [2]. Business Segments - The revenue from the pharmaceutical research segment is expected to decline sharply from 131 million yuan in 2024 to 43.44 million yuan in 2025, a decrease of 66.87%, primarily due to industry pressures and reduced new orders [2]. - The target company's reliance on technology transfer for profit is increasing, with this segment accounting for 52.92% of total revenue in 2025, growing by 104.67% compared to 2024 [3]. Acquisition Justification - The valuation for the acquisition is based on an income approach, with the target company's 100% equity valued at 759 million yuan, resulting in a premium of 474 million yuan and a premium rate of 166.73% [4]. - China Pharmaceutical asserts that the valuation is cautious and reasonable, supported by the progress of ongoing projects and comparisons with industry peers [4]. Risk Management - To mitigate risks associated with the acquisition, several measures have been implemented, including staggered payments to founding shareholders and loss compensation agreements [5]. - The company has faced challenges in its own operations, with a reported revenue decline of 3.42% year-on-year for the first three quarters of 2025, and a net profit decrease of 4.64%, marking five consecutive years of decline [6].

Core Viewpoint - China Medical Health Industry Co., Ltd. is holding an investor briefing on asset acquisition to address investor concerns and provide detailed information about the transaction [2][3][11]. Group 1: Meeting Details - The investor briefing is scheduled for January 28, 2026, from 15:00 to 16:00 at the Shanghai Stock Exchange Roadshow Center [2][6]. - The meeting will be conducted via video and online interaction, allowing investors to submit questions in advance [3][5]. - Key personnel attending the meeting include the Chairman/General Manager, Chief Accountant, and Secretary of the Board [4]. Group 2: Financial Performance of the Target Company - The target company, Shanghai Zezheng Pharmaceutical Technology Co., Ltd., experienced a significant decline in performance in 2025, with a net profit drop of 75.99% and a revenue decrease of 12.24% compared to 2024 [11][30]. - The revenue for 2025 was approximately 225.51 million yuan, down from 258.69 million yuan in 2024, while the net profit was 9.44 million yuan, compared to 39.34 million yuan in 2024 [12][30]. - The decline in revenue was primarily attributed to a 66.87% drop in the pharmaceutical research business, which fell from 131.15 million yuan in 2024 to 43.44 million yuan in 2025 [25][30]. Group 3: Business Segments and Strategy - The target company has shifted its business strategy towards technology transfer, which accounted for 52.92% of total revenue in 2025, showing a growth of 104.67% year-on-year [26][33]. - The company has a robust pipeline of 67 ongoing research projects, which supports future technology transfer opportunities [31][33]. - The company aims to focus on high-value segments in the CRO industry and expand its client base to ensure sustainable growth in its research services [30][31]. Group 4: Risk Factors - The target company faces risks related to the performance decline of its CRO business, which is highly competitive, and the potential for further revenue drops if market conditions worsen [9][10]. - There are concerns regarding the sustainability of the technology transfer business, as it heavily relies on successful project development and market demand [9][10]. - The company has acknowledged the risk of goodwill impairment due to the high valuation of the acquisition relative to the target company's declining performance [10].

证券代码：600056 证券简称：中国医药 公告编号：临2026-006号 中国医药健康产业股份有限公司 关于回复购买资产有关事项监管工作函的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 特别风险提示： 1.标的公司业绩大幅下滑及CRO业务（即研发服务业务，下同）萎缩风险： 标的公司所处的CRO行业属于充分竞争行业，行业存在竞争加剧的风险,从而对 其CRO业务带来不利影响。2025年标的公司净利润下降75.99%，其中CRO业务 收入同比下滑46.44%，新签订单金额同比减少30.81%，可能因CRO业务萎缩造 成其业绩进一步下滑风险。 2.技术转让业务可持续性风险：2025年标的公司技术转让业务毛利占比超过 85%，对技术转让业务的利润依赖度较高。标的公司有部分存量自研项目仍在推 进中，存在因技术或临床等原因造成研发进度延迟、上市受阻或上市后收益不及 预期等不确定性情况，同时其技术转让业务能否实现转让存在不确定性，未来可 能存在可持续性风险，从而对其盈利能力造成不利影响。 3.交易估值相对较高及商誉减值风险：本次交易 ...

证券代码：600056 证券简称：中国医药 公告编号：临 2026-007 号 中国医药健康产业股份有限公司 关于召开购买资产有关事项投资者说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （二）会议召开地点：上证路演中心 （三）会议召开方式：视频和网络互动 三、 参加人员 公司董事长/总经理、总会计师及董事会秘书（如有特殊情况， 参会人员可 能进行调整）。 投资者可于 2026 年 1 月 22 日（星期四）至 1 月 27 日（星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 meheco600056@meheco.gt.cn 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 中国医药健康产业股份有限公司（以下简称"公司"）于 2025 年 12 月 31 日发布关于购买资产的公告，为便于广大投资者更全面深入地了解本次交易的相 关情况，公司计划于 2026 年 1 月 28 日（星期三）15:00-16:00 举行关于购买资 产有关事项的投资者说明会 ...